Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2]. |
In vitro | UC-1V150, at concentrations ranging from 0.01 to 10 μM over a 24-hour period, effectively promotes the secretion of IL-6 and IL-2 cytokines in bone-marrow-derived macrophages [1]. Additionally, when administered at 1 μg/mL for 48 hours, it enhances the expression of FcγRIIA and FcγRIII and induces a roughly 1.5-fold enhancement in the phagocytosis index of target cells in human monocyte-derived macrophages (hMDM) [2]. |
In vivo | UC-1V150, administered via a single intravenous injection at concentrations ranging from 0.38-38 nM for 2 hours, effectively triggers the release of serum cytokines in female C57BL/6 mice aged 5-6 weeks. This administration resulted in serum interleukin-6 (IL-6) levels reaching approximately 0.1 ng/mL and interleukin-2 (IL-2) levels reaching approximately 1.5 ng/mL at the 38 nM concentration. |
Molecular Weight | 343.34 |
Formula | C16H17N5O4 |
CAS No. | 927822-45-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UC-1V150 927822-45-5 inhibitor inhibit